Floatz logo

MONOCLONAL ANTIBODY BC8

Allogeneic Disease

Actinium Pharmaceuticalsmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Allogeneic Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 4BBB
Busulphan
City of Hope Medical Center
Phase 4BBB
Thiotepa
Memorial Sloan Kettering Cancer Center
Phase 4BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

MONOCLONAL ANTIBODY BC8 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
B
Indicative ·
60 / 100
View asset →
Myelogenous LeukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →